烏龍製藥 URGN 深 滬
等待開盤 09-17 09:30:00 美东时间
43.49
+1.750
+4.19%
華盛通- 最 高43.72
- 今 開42.07
- 成交量 99.72万股
- 最 低 42.07
- 昨 收 41.74
- 總市值 21.26亿
- 52周最高 50.81
- 市盈率 靜 --
- 換手率 2.04%
- 52周最低 15.86
- 委 比 69.37%
- 總股本 4888.06万
- 歷史最高 69.568
- 量 比 1.44
- 振 幅 3.95%
- 歷史最低 3.42
- 每 手 1
- 風險率 9.40%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma Ltd. has granted inducement restricted stock units (RSUs) to 19 new employees to support the commercialization of its approved products, JELMYTO® and ZUSDURI™, and pipeline development. The RSUs, totaling up to 117,100 shares, vest equally over three years. The grants align with Nasdaq Listing Rule 5635(c)(4) and UroGen’s 2019 Inducement Plan. UroGen, headquartered in Princeton, NJ, specializes in innovative treatments for urothelia...
09-04 12:00
UroGen Pharma to Present at Upcoming Investor Conferences
UroGen Pharma Ltd. will participate in three investor conferences in September 2026. The events include the Wells Fargo 21st Annual Healthcare Conference on September 9th in Boston, the Cantor Global Healthcare Conference 2026 on September 10th in New York, and the H.C. Wainwright 28th Annual Global Investment Conference on September 15th in New York. Each session will be a Fireside Chat and webcast links are provided. The webcasts will also be a...
09-02 12:00
UroGen Pharma Announces Strategic Option And Research License Agreement And Related Equity Investment Agreement With IntraGel Therapeutics
Collaboration grants UroGen a research license and exclusive options to license and develop up to three oncology products utilizing IntraGel's proprietary SRGel platform Agreement also includes an exclusive option to acquire worldwide rights to TumoCure, an investigational therapy for advanced head ...
08-20 19:02
UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC
UroGen Pharma announced the submission of an NDA to the FDA for UGN-103, a next-generation mitomycin formulation for treating recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). UGN-103 builds on ZUSDURI, the first FDA-approved treatment for this indication, with improvements in manufacturing, reconstitution, and shelf-life. The submission is supported by Phase 3 UTOPIA trial data showing a 77.8% three-month co...
08-17 12:00
美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $58
Guggenheim analyst Michael Schmitz maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $42 to $58.
08-06 21:48
UroGen Pharma shares are trading higher after the company reported better-than-expected Q2 financial results.
UroGen Pharma shares are trading higher after the company reported better-than-expected Q2 financial results.
08-05 21:08
UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026
UroGen Pharma Ltd. (Nasdaq: URGN) announced it will report its second quarter 2026 financial results on August 5, 2026, followed by a live audio webcast and conference call at 10:00 AM ET. The webcast will be available on UroGen’s Investor Relations website, with a replay accessible for 30 days. UroGen is a biotech company focused on developing innovative treatments for urothelial and specialty cancers using its proprietary RTGel® technology, whi...
07-29 12:00
Biotech stocks lead healthcare's overbought list as earnings picks up
Healthcare stocks are in focus as second-quarter earnings season shifts into high gear, with investors evaluating whether recent rallies across biotech, medical technology and healthcare services can ...
07-23 19:18
美股大行评级 | 富国银行上调亚马逊目标价从313美元升至322美元；潜在涨幅370.99%！HC Wainwright上调Greenwich LifeSciences目标价至69美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Greenwich LifeSciences"买入"评级，目标价从50美元升至69美元；高盛：维持Taysha Gene Therapies"买入"评级，目标价从11美元升至13美元
07-22 11:35
